Huaier Granule in Patients With Stage I Primary Ovarian Fallopian Tube Cancer After Peritoneal Cancer
Status:
Not yet recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This study is an exploratory, single-center, prospective single-arm study to explore the
efficacy of Huaier granules in the treatment of stage Ⅱ-Ⅳ primary ovarian cancer, fallopian
tube cancer, and peritoneal cancer after satisfactory tumor reduction (R0/R1). Twenty-five
patients with FIGOⅡ-Ⅳ ovarian cancer, peritoneal cancer or tubal cancer confirmed by
histopathology were enrolled and treated with Huaier granules. During the study period, the
patients were followed up once at 3 months, and the medication was continued until
progression or intolerability of toxicity. This is an exploratory, single-center, prospective
single-arm study to explore the efficacy of Huaier granules in the treatment of stage Ⅱ-Ⅳ
primary ovarian cancer, fallopian tube cancer, and peritoneal cancer after satisfactory tumor
reduction (R0/R1). Twenty-five patients with FIGOⅡ-Ⅳ ovarian cancer, peritoneal cancer or
tubal cancer confirmed by histopathology were enrolled and treated with Huaier granules.
During the study period, the patients were followed up once at 3 months, and the medication
was continued until progression or intolerability of toxicity.